Skip to main content

Immunotherapies for Neurologic Diseases

  • 1st Edition, Volume 214 - January 18, 2026
  • Latest edition
  • Editor: Marinos C. Dalakas
  • Language: English

Immunotherapies for Neurologic Diseases, Volume 214 explores how neuroimmunotherapies intervene by targeting key molecules and pathways responsible for tissue damage in the centr… Read more

Early spring sale

Nurture your knowledge

Grow your expertise with up to 25% off trusted resources.

Description

Immunotherapies for Neurologic Diseases, Volume 214 explores how neuroimmunotherapies intervene by targeting key molecules and pathways responsible for tissue damage in the central and peripheral nervous systems. The book details approved treatments that modulate T-cell signaling, antigen presentation, B cells and their trophic factors, autoantibodies, Fc receptors, complement, cytokines, and cell adhesion molecules. Each chapter includes clear explanations and illustrations, helping clinicians understand the mechanisms of these drugs in autoimmune neurological diseases. The volume serves as a practical and comprehensive guide, making complex therapeutic approaches accessible to medical professionals and students.

The second section highlights the latest therapies for major autoimmune neurological diseases, offering step-by-step algorithms and escalation strategies for selecting optimal treatments. Controversies and uncertainties in therapy choices are discussed by leading experts, while additional chapters address emerging immunotherapeutic approaches for neurodegenerative diseases and the evolving concept of treating autoimmune pain. The book also covers practical applications of traditional immunosuppressants, IVIg, and targeted monoclonal antibodies, with dedicated chapters on conditions such as encephalitis, NMOSD, multiple sclerosis, and stiff person syndrome.

Key features

  • Summarizes and consolidates new research on immunotherapies for neurologic diseases
  • Identifies how immunotherapies work
  • Includes monoclonal antibodies or fusion proteins against B cells, T cells, and FcRn
  • Provides treatment algorithms and escalating therapies for common diseases
  • Highlights new agents in pipeline orin early trials

Readership

Clinical neurologists

Table of contents

SECTION I Introduction to neuro-immunotherapies

1. Progress of neuroimmunotherapies: Witnessing an impressive success in the treatment of neurologic autoimmunities
SECTION II Evolution of autoimmune neurology

2. Autoimmune encephalitis, autoimmune dementias, and autoimmune psychotic disorders

3. The history of paraneoplastic neurologic disorders of the CNS, PNS, and autonomic nervous systems: Perspective on the past toward a brighter future
SECTION III Basic principles of immune activation in neurologic diseases as related to targeted immunotherapies

4. Role of B cells and pathogenic autoantibodies in autoimmune CNS and PNS neurologic diseases

5. Role of complement in neurologic autoimmunities: Why need to target complement activation for effective immunotherapy

6. Paraneoplastic neurologic disorders and neurologic complications of immune checkpoint inhibitors
SECTION IV Immunotherapeutic agents in autoimmune neurologic diseases: Current and evolving biologics

7. The evolution and current status of anti-B-cell therapies in autoimmune neurologic diseases

8. Evolving targeted biologics against T cells, cytokines, and intracellular immune targets for multiple sclerosis with implications in other autoimmune neurologic diseases

9. FcRn inhibitors: A new era in neurotherapeutics

10. Intravenous immunoglobulin use in neurology

11. Hematopoietic stem cell transplantation for multiple sclerosis: Improving understanding and addressing misconceptions
SECTION V Immunotherapies for specific neurologic diseases (how do I do it): A step-by step approach based on evidence-based indications with a view to the future

12. Immunotherapies in progressive multiple sclerosis

13. Disease-modifying therapy in pediatric multiple sclerosis

14. Immunotherapies for neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease

15. Immunotherapies on autoimmune encephalitis

16. Immunotherapies in autoimmune movement disorders and cerebellar ataxia

17. Immunobiology and immunotherapies in stiff-person syndrome and glutamic acid decarboxylase antibody-spectrum disorders: Present and future therapeutic prospects

18. Immunotherapies on Guillain–Barré syndrome and other acute autoimmune neuropathies

19. Immunotherapies in chronic immune-mediated neuropathies

20. Autonomic nervous system autoimmunity and proposed immunotherapies

21. Immunotherapy considerations for distal sensory-predominant and small-fiber peripheral neuropathies

22. Immunotherapies in autoimmune neuromuscular junction disorders: Acute and chronic management

23. Immunotherapies in autoimmune inflammatory myopathies: Rationale and therapeutic updates

24. The future unfolded: CAR T cells and the transformation of treatment algorithms in autoimmune neurology

Product details

  • Edition: 1
  • Latest edition
  • Volume: 214
  • Published: February 16, 2026
  • Language: English

About the editor

MD

Marinos C. Dalakas

Dr. Marinos Dalakas is Professor of Neurology and Director of the Neuromuscular Division at Thomas Jefferson University School of Medicine in Philadelphia. He is Professor of Neurology and Chief of the Neuroimmunology Laboratory in the Department of Pathophysiology at the University of Athens Medical School in Athens, where he has been Emeritus Professor since 2016. Dr. Dalakas is an appointed member in various scientific societies and is a member of the American Neurological Association, the American Academy of Neurology, the European Neurological Society, and the International Society of Greek Neuroscientists, among other professional organizations. Dr. Dalakas has published widely. His areas of research are broad and include neuroimmunology, neurovirology, genetics, and immunotherapies in neurologic diseases. He has focused on neuropathies, myopathies, dystrophies, ALS, multiple sclerosis, and various autoimmune neurological disorders, with the application and design of new treatments. He completed a 3-year fellowship training in neuromuscular diseases at the Medical Neurology Branch of the NINCDS in Bethesda, Maryland and an additional 5-year training in Neuroimmunology/Neurovirology at NINDS. He subsequently served as Chief of the Neuromuscular Diseases Section of the NINDS, NIH, a position he held for 20 years before joining Thomas Jefferson University.
Affiliations and expertise
Professor of Neurology, Thomas Jefferson University School of Medicine, Philadelphia, USA

View book on ScienceDirect

Read Immunotherapies for Neurologic Diseases on ScienceDirect